• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
  • Featured Product
  • KD/KO Validated

Palladin Polyclonal antibody

Palladin Polyclonal Antibody for FC, IF, IHC, IP, WB,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse and More (1)

Applications

WB, IP, IHC, IF, FC, COIP

Conjugate

Unconjugated

Cat no : 10853-1-AP

Synonyms

CGI 151, KIAA0992, palladin, PALLD, PNCA1, Sarcoma antigen NY SAR 77, SIH002

Validation Data Gallery

Applications:
  • WB analysis of A549 cells using 10853-1-AP

    WB analysis of A549 cells using 10853-1-AP

    A549 cells (shcontrol and shRNA of PALLD) were subjected to SDS PAGE followed by western blot with 10853-1-AP (PALLD antibody) at dilution of 1:2000.

  • WB analysis of HeLa using 10853-1-AP

    WB analysis of HeLa using 10853-1-AP

    HeLa cells were subjected to SDS PAGE followed by western blot with 10853-1-AP (Palladin antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

  • WB analysis of HepG2 using 10853-1-AP

    WB analysis of HepG2 using 10853-1-AP

    HepG2 cells were subjected to SDS PAGE followed by western blot with 10853-1-AP (Palladin antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

  • WB analysis of mouse kidney using 10853-1-AP

    WB analysis of mouse kidney using 10853-1-AP

    mouse kidney tissue were subjected to SDS PAGE followed by western blot with 10853-1-AP (PALLD,palladin Antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

  • WB analysis of HeLa using 10853-1-AP

    WB analysis of HeLa using 10853-1-AP

    HeLa cells were subjected to SDS PAGE followed by western blot with 10853-1-AP (Palladin antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours.

  • IP experiment of HeLa using 10853-1-AP

    IP experiment of HeLa using 10853-1-AP

    IP Result of anti-Palladin (IP:10853-1-AP, 4ug; Detection:10853-1-AP 1:2000) with HeLa cells lysate 1800ug.

  • IP experiment of HEK-293 using 10853-1-AP

    IP experiment of HEK-293 using 10853-1-AP

    IP Result of anti-Palladin (IP:10853-1-AP, 4ug; Detection:10853-1-AP 1:300) with HEK-293 cells lysate 1500ug.

  • IHC staining of human colon cancer using 10853-1-AP

    IHC staining of human colon cancer using 10853-1-AP

    Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 10853-1-AP (PALLD,palladin Antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

  • IHC staining of human colon cancer using 10853-1-AP

    IHC staining of human colon cancer using 10853-1-AP

    Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 10853-1-AP (PALLD,palladin Antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

  • IHC staining of human colon using 10853-1-AP

    IHC staining of human colon using 10853-1-AP

    Immunohistochemical analysis of paraffin-embedded human colon using 10853-1-AP (Palladin antibody) at dilution of 1:50 (under 10x lens).

  • IHC staining of human colon using 10853-1-AP

    IHC staining of human colon using 10853-1-AP

    Immunohistochemical analysis of paraffin-embedded human colon using 10853-1-AP (Palladin antibody) at dilution of 1:50 (under 40x lens).

  • IHC staining of human ovary tumor using 10853-1-AP

    IHC staining of human ovary tumor using 10853-1-AP

    Immunohistochemical analysis of paraffin-embedded human ovary tumor using 10853-1-AP (Palladin antibody) at dilution of 1:100 (under 10x lens).

  • IHC staining of human colon cancer using 10853-1-AP

    IHC staining of human colon cancer using 10853-1-AP

    Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 10853-1-AP (PALLD,palladin Antibody) at dilution of 1:50 (under 10x lens).

  • IHC staining of human colon cancer using 10853-1-AP

    IHC staining of human colon cancer using 10853-1-AP

    Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 10853-1-AP (PALLD,palladin Antibody) at dilution of 1:50 (under 40x lens).

  • IHC staining of human breast cancer using 10853-1-AP

    IHC staining of human breast cancer using 10853-1-AP

    Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 10853-1-AP (PALLD,palladin Antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

  • IHC staining of human breast cancer using 10853-1-AP

    IHC staining of human breast cancer using 10853-1-AP

    Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 10853-1-AP (PALLD,palladin Antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

  • IF Staining of HeLa using 10853-1-AP

    IF Staining of HeLa using 10853-1-AP

    Immunofluorescent analysis of HeLa cells using 10853-1-AP (Palladin antibody) at dilution of 1:50 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

  • FC experiment of HeLa using 10853-1-AP

    FC experiment of HeLa using 10853-1-AP

    1X10^6 HeLa cells were stained with 0.2ug PALLD,palladin antibody (10853-1-AP, red) and control antibody (blue). Cells were fixed with 4% PFA and permeabilized with 0.1% Triton X-100. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) with dilution 1:1000.

Tested Applications

Positive WB detected inHeLa cells, A549 cells
Positive IP detected inHeLa cells, HEK-293 cells
Positive IHC detected inhuman colon cancer tissue, human breast cancer tissue, human colon tissue, human ovary tumor tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHeLa cells
Positive FC detected inHeLa cells
Planning an IF experiment? We recommend our CoraLite®488, CoraLite®555 and CoraLite®594 conjugated versions of this antibody.

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:1000-1:4000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:1000-1:4000 for WB
Immunohistochemistry (IHC)IHC : 1:50-1:500
Immunofluorescence (IF)IF : 1:20-1:200
Sample-dependent, check data in validation data gallery

Product Information

10853-1-AP targets Palladin in WB, IP, IHC, IF, FC, COIP applications and shows reactivity with human, mouse samples.

Tested Reactivity human, mouse
Cited Reactivityhuman, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Palladin fusion protein Ag1288
Full Name palladin, cytoskeletal associated protein
Calculated molecular weight 1383 aa, 151 kDa
Observed molecular weight 95 kDa, 140 kDa
GenBank accession numberBC013867
Gene symbol PALLD
Gene ID (NCBI) 23022
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

Palladin is an actin associated protein serving as a cytoskeleton scaffold, and actin cross linker, localizing at stress fibers, focal adhesions, and other actin based structures. Palladin exists as multiple isoforms through alternative transcription initiation sites and splicing. There are three major isoforms (200, 140, 90-92 kDa) and multiple minor isoforms. Different palladin isoforms are expressed in a tissue-specific pattern during development and in adult organs: the 200 kDa isoform is predominantly expressed in the heart, skeletal muscle, testis and bone; the 140 kDa isoform is widely expressed with the exception of liver, muscle, and skin; the 90-92 kDa isoform is broadly expressed in embryonic tissues and highly expressed in adult smooth muscle tissues (21455759). Recently overexpression of palladin has been linked to the promoted invasive motility in several types of cancers (18978809, 22291919). The 85-90 kDa palladin isoform has been observed predominantly expressed in pancreatic ductal adenocarcinoma (PDA) while a 65 kDa isoform is expressed in normal pancreas and non-PDA tumors (20436683). This antibody, generated against the fragment 999-1383aa of palladin, recognizes most isoforms of this protein, except isoform 6.

Protocols

Product Specific Protocols
WB protocol for Palladin antibody 10853-1-APDownload protocol
IHC protocol for Palladin antibody 10853-1-APDownload protocol
IF protocol for Palladin antibody 10853-1-APDownload protocol
IP protocol for Palladin antibody 10853-1-APDownload protocol
FC protocol for Palladin antibody 10853-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
ratIF

Spermatogenesis

Actin cross-linking protein palladin and spermatogenesis.

Authors - Qian Xiaojing X
View Article
humanWB

Biochim Biophys Acta

Differential phosphorylation of Akt1 and Akt2 by protein kinase CK2 may account for isoform specific functions.

Authors - Cristina Girardi
View Article
humanIF

Acta Biomater

TGFβ functionalized starPEG-heparin hydrogels modulate human dermal fibroblast growth and differentiation.

Authors - Akira Watarai
View Article
WB

Cytoskeleton (Hoboken)

Palladin expression is a conserved characteristic of the desmoplastic tumor microenvironment and contributes to altered gene expression.

Authors - Austin R Cannon
View Article
ratWB

Spermatogenesis

Overexpression of plastin 3 in Sertoli cells disrupts actin microfilament bundle homeostasis and perturbs the tight junction barrier.

Authors - Nan Li
View Article
ratWB,IF

Am J Physiol Endocrinol Metab

Dynein 1 supports spermatid transport and spermiation during spermatogenesis in the rat testis.

Authors - Qing Wen
View Article